267 related articles for article (PubMed ID: 34089171)
21. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
22. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
23. Impact of testosterone treatment on circulating irisin in men with late-onset hypogonadism and metabolic syndrome.
Assyov Y; Gateva A; Karamfilova V; Gatev T; Nedeva I; Velikova T; Kamenov ZA
Aging Male; 2020 Dec; 23(5):1381-1387. PubMed ID: 32456511
[TBL] [Abstract][Full Text] [Related]
24. Testosterone Replacement Therapy in Hypogonadal Men and Myocardial Infarction Risk: Systematic Review & Meta-Analysis.
Lee JH; Shah PH; Uma D; Salvi DJ; Rabbani R; Hamid P
Cureus; 2021 Aug; 13(8):e17475. PubMed ID: 34513525
[TBL] [Abstract][Full Text] [Related]
25. Testosterone replacement therapy: Pre-treatment sex hormone-binding globulin levels and age may identify clinical subgroups.
Ramachandran S; Hackett GI; Strange RC
Andrology; 2020 Sep; 8(5):1222-1232. PubMed ID: 32384175
[TBL] [Abstract][Full Text] [Related]
26. Effect of testosterone replacement therapy on vitamin D and FGF-23 levels in congenital hypogonadism.
Haymana C; Sonmez A; Aydogdu A; Tapan S; Basaran Y; Meric C; Baskoy K; Taslipinar A; Yilmaz MI; Azal O
Endokrynol Pol; 2017; 68(3):311-616. PubMed ID: 28230890
[TBL] [Abstract][Full Text] [Related]
27. Testosterone supplementation and bone parameters: a systematic review and meta-analysis study.
Corona G; Vena W; Pizzocaro A; Giagulli VA; Francomano D; Rastrelli G; Mazziotti G; Aversa A; Isidori AM; Pivonello R; Vignozzi L; Mannucci E; Maggi M; Ferlin A
J Endocrinol Invest; 2022 May; 45(5):911-926. PubMed ID: 35041193
[TBL] [Abstract][Full Text] [Related]
28. Controversial aspects of testosterone in the regulation of sexual function in late-onset hypogonadism.
Maggi M; Filippi S; Vignozzi L; Rastrelli G
Andrology; 2020 Nov; 8(6):1580-1589. PubMed ID: 32248652
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes.
Corona G; Rastrelli G; Maggi M
Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):557-79. PubMed ID: 24054931
[TBL] [Abstract][Full Text] [Related]
30. Effects of Testosterone Replacement Therapy on Muscle Strength in Older Men with Low to Low-Normal Testosterone Levels: A Systematic Review and Meta-Analysis.
Lee TW; Kao PY; Chen YC; Wang ST
Gerontology; 2023; 69(10):1157-1166. PubMed ID: 37494893
[TBL] [Abstract][Full Text] [Related]
31. Testosterone replacement therapy for late-onset hypogonadism: current trends in Korea.
Ko YH; Kim JJ
Asian J Androl; 2011 Jul; 13(4):563-8. PubMed ID: 21572448
[TBL] [Abstract][Full Text] [Related]
32. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
33. The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis.
Cui Y; Zong H; Yang C; Yan H; Zhang Y
Int Urol Nephrol; 2013 Aug; 45(4):979-87. PubMed ID: 23728850
[TBL] [Abstract][Full Text] [Related]
34. Late-onset hypogonadism and lifestyle-related metabolic disorders.
Braga PC; Pereira SC; Ribeiro JC; Sousa M; Monteiro MP; Oliveira PF; Alves MG
Andrology; 2020 Nov; 8(6):1530-1538. PubMed ID: 31991053
[TBL] [Abstract][Full Text] [Related]
35. Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects.
Antonio L; Caerels S; Jardi F; Delaunay E; Vanderschueren D
Andrology; 2019 May; 7(3):302-306. PubMed ID: 30851011
[TBL] [Abstract][Full Text] [Related]
36. Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE).
Isidori AM; Aversa A; Calogero A; Ferlin A; Francavilla S; Lanfranco F; Pivonello R; Rochira V; Corona G; Maggi M
J Endocrinol Invest; 2022 Dec; 45(12):2385-2403. PubMed ID: 36018454
[TBL] [Abstract][Full Text] [Related]
37. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
[TBL] [Abstract][Full Text] [Related]
38. Association between prostate-specific antigen and serum testosterone: A systematic review and meta-analysis.
Kim DK; Noh JW; Chang Y; Lee HY; Park JJ; Ryu S; Kim JH
Andrology; 2020 Sep; 8(5):1194-1213. PubMed ID: 32329181
[TBL] [Abstract][Full Text] [Related]
39. The effect of physiotherapy in addition to testosterone replacement therapy on the efficiency of the motor system in men with hypogonadism.
Bacevičienė R; Valonytė L; Ceponis J
Medicina (Kaunas); 2013; 49(2):71-7. PubMed ID: 23888342
[TBL] [Abstract][Full Text] [Related]
40. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes.
Groti K; Žuran I; Antonič B; Foršnarič L; Pfeifer M
Aging Male; 2018 Sep; 21(3):158-169. PubMed ID: 29708829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
